Table 1.
Blockade | Compound or antibody | Pathogen model | Role of antagonist | Reference |
---|---|---|---|---|
Receptor antagonists | ||||
CCR2 | RS504393 | SFV | No effect | Michlmayr et al. (2014) |
CCR5 | DAPTA | SFV | No effect | Michlmayr et al. (2014) |
CXCR3 | Compound 21 | SFV | No effect | Michlmayr et al. (2014) |
CXCR3 & CCR2 | Compound 21 and RS504393 | SFV | Beneficial | Michlmayr et al. (2014) |
CXCR4 | AMD3100 | WNV | Beneficial | McCandless et al. (2008) |
Antibodies | ||||
CXCL10 | 1F11 or 1B9 | WNV | Pathogenic | Klein et al. (2005) |
CCL2 | 2H5 | WNV | Beneficial | Getts et al. (2008) |
The role of chemokine/receptor blockade can be either beneficial, pathogenic or have no effect on disease outcome in murine models of encephalitis.